Malejczyk J, Osiecka A, Hyc A, Moskalewski S
Department of Histology and Embryology, Warsaw Medical School, Warsaw, Poland.
Clin Orthop Relat Res. 1991 Aug(269):266-73.
The effect of short-term immunosuppressive treatment with antithymocyte serum-procarbazine (ATS-PCH) and cyclosporin-A (Cy-A) on survival of allogeneic rib chondrocyte grafts was examined morphologically and by evaluation of specific humoral and cellular antigraft immunity. The latter were evaluated by means of leukoagglutination and the indirect migration inhibition assay, respectively. Untreated recipients of syngeneic rib chondrocytes and untreated recipients of whole syngeneic and allogeneic rib cartilage served as controls. Transplanted syngenic rib chondrocytes formed cartilaginous nodules similar to rib cartilage in situ. These nodules contained hypertrophied chondrocytes, but neither physiologic resorption by vascularized connective tissue nor bone formation occurred after an observation period of longer than six weeks. Transplantation of allogeneic chondrocytes resulted in development of humoral and cellular antigraft immunity, and the formed cartilage was destroyed by infiltrating immune cells. Immunosuppression by ATS-PCH resulted in inhibition of graft destruction and a marked decrease of specific humoral antigraft immunity. Cellular antigraft immunity did not occur. Moreover, neither the histologic appearance of the cartilaginous nodules nor the results of immunologic response evaluations in the ATS-PCH-treated group differed from those in untreated whole allogeneic cartilage recipients. Treatment with Cy-A did not significantly improve survival cartilage formed by allogeneic chondrocytes.
采用抗胸腺细胞血清-甲基苄肼(ATS-PCH)和环孢素A(Cy-A)进行短期免疫抑制治疗,对同种异体肋软骨细胞移植存活的影响,通过形态学检查以及对特异性体液和细胞抗移植免疫进行评估。后者分别通过白细胞凝集试验和间接移动抑制试验进行评估。同基因肋软骨细胞未治疗的受体以及全同基因和同种异体肋软骨未治疗的受体作为对照。移植的同基因肋软骨细胞形成了与原位肋软骨相似的软骨结节。这些结节含有肥大的软骨细胞,但在超过六周的观察期后,既没有发生血管化结缔组织的生理性吸收,也没有发生骨形成。同种异体软骨细胞移植导致体液和细胞抗移植免疫的产生,形成的软骨被浸润的免疫细胞破坏。ATS-PCH免疫抑制导致移植破坏受到抑制,特异性体液抗移植免疫显著降低。未出现细胞抗移植免疫。此外,ATS-PCH治疗组软骨结节的组织学表现以及免疫反应评估结果与未治疗的同种异体全软骨受体组并无差异。Cy-A治疗并未显著提高同种异体软骨细胞形成的存活软骨。